The 3.75% convertible notes are due 2029

Davis Polk advised the initial purchaser in connection with a Rule 144A offering by OPKO Health, Inc. of $230 million aggregate principal amount of its 3.75% convertible senior notes due 2029, which included $30 million principal amount of notes pursuant to the exercise in full of the initial purchaser’s option to purchase additional notes.

OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and its novel and proprietary technologies.

The Davis Polk corporate team included partner Deanna L. Kirkpatrick and associate Rahul K. Patel. The equity derivatives team included partner Mark J. DiFiore and associates Greg Marchesini and Ji Hwan Kim. Partner Michael Farber and associates Justin Corvino and Michael Hsieh provided tax advice. Partner David R. Bauer and associate Francesca Masella provided intellectual property advice. All members of the Davis Polk team are based in the New York office.